Alk­er­mes forges $950M biotech buy­out deal in a bold bet on an ear­ly-stage CNS drug plat­form

Alk­er­mes $ALKS is in­vest­ing $100 mil­lion cash and com­mit­ting up to $850 mil­lion more in mile­stones in a big wa­ger on a very ear­ly-stage CNS dis­cov­ery plat­form. And the biotech is adding $20 mil­lion more to fund next year’s new re­search work on the plat­form it’s ac­quir­ing in to­day’s buy­out with an eye to ex­pand­ing the re­search work in on­col­o­gy.

The biotech, helmed by Richard Pops, is buy­ing Rodin Ther­a­peu­tics, which had fo­cused ear­ly on Alzheimer’s dis­ease. Pops’ buy­out, though, isn’t fo­cused sole­ly on the most trou­ble­some sec­tor in phar­ma R&D.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.